Advanced Biomedical Instrumentation Centre (ABIC) aims to foster collaboration among top-notch engineers, scientists, and clinicians in Hong Kong and the world to develop next-generation and low-cost medical instrumentation, as well as to facilitate the commercialization of research results into real-world applications that are accessible to a broader population.

Centre for Immunology & Infection (C2i) addresses significant public healthcare challenges through the establishment of a novel technology platform for biomarker discovery and the development of new vaccine and therapeutic strategies. The Centre enhances Hong Kong’s knowledge-based economy and provides state-of-the-art training for the local population.

Centre for Oncology and Immunology (COI) is co-directed by Professor Tak MAK and Professor Suet Yi LEUNG from HKUMed with the aim to develop innovative therapeutics in immuno-oncology for cancers that are prevalent in Asia and to establish Hong Kong as an international biotechnology hub for therapeutic development.

Centre for Translational Stem Cell Biology (CTSCB) strives to translate stem cell research discoveries into novel stem cell technologies and products originated from Expanded Potential Stem Cells (EPSCs). These will be applied to regenerative medicine, autoimmunity and genomic medicine.

Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) aims at integrating Chemical and Biomedical Sciences for the treatment of diseases with an emphasis on cancer. The Laboratory shall evolve into a world class centre of novel therapeutics and diagnostics discovery, whose accomplishments shall showcase Hong Kong’s capacity to develop innovative chemical and biomedical research enterprises.

Proactive and effective “surveillance and control” of epidemic infectious diseases outbreaks relies on the comprehensive knowledge of the viruses circulating in animals and human, reliable prediction of the potential of these animal viruses to jump interspecies barrier from animal to human, highly-multiplex diagnostic tests for rapid detection of these viruses in healthcare and field setting, broad spectrum antivirals for prophylactic and therapeutic treatment, and most importantly, a safe and towards-universal vaccine platform with heterologous protection against antigenically drifted viruses. Centre for Virology, Vaccinology and Therapeutics (CVVT) is set to provide these conditions.